Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17289590
Sapkota G, et al. (2007) Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell 25, 441-54 17289590
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 increase L/L mutant- lacks 4 MAPK and 1 GSK3 site
BMP2 increase slight increase
EGF increase
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
U0126 no change compared to control
U0126 BMP2 inhibit treatment-induced increase
U0126 EGF inhibit treatment-induced increase

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BMP2 no change compared to control
EGF no change compared to control
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
SB203580 no change compared to control
SB203580 UV inhibit treatment-induced increase
SP600125 UV augment treatment-induced increase

S187-p - SMAD1 (human)
Modsite: NSHPFPHsPNSSYPN SwissProt Entrez-Gene
Orthologous residues
SMAD1 (human): S187‑p, SMAD1 (mouse): S187‑p, SMAD1 (rat): S187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human

S195-p - SMAD1 (human)
Modsite: PNSSYPNsPGSSSSt SwissProt Entrez-Gene
Orthologous residues
SMAD1 (human): S195‑p, SMAD1 (mouse): S195‑p, SMAD1 (rat): S195‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human

T202-p - SMAD1 (human)
Modsite: sPGSSSStYPHsPTS SwissProt Entrez-Gene
Orthologous residues
SMAD1 (human): T202‑p, SMAD1 (mouse): T202‑p, SMAD1 (rat): T202‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)

S206-p - SMAD1 (human)
Modsite: SSStYPHsPTSSDPG SwissProt Entrez-Gene
Orthologous residues
SMAD1 (human): S206‑p, SMAD1 (mouse): S206‑p, SMAD1 (rat): S206‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FGF1 increase wild-type
FGF1 no effect upon treatment-induced decrease L/L mutant
BMP2 increase
EGF increase
UV increase
insulin no change compared to control
hypertonic_buffer increase
TGF-beta increase
EGF no change compared to control nuclear
BMP2, EGF BMP2 augment treatment-induced increase nuclear
EGF increase slight increase, cytosolic
BMP2 EGF augment treatment-induced increase cytosolic
Downstream Regulation
Effect of modification (function):  intracellular localization, molecular association, regulation, protein degradation, ubiquitination
Comments:  SMURF1 binds phosphorylated SMAD1 causing cytoplasmic retention or degredation

S214-p - SMAD1 (human)
Modsite: PTSSDPGsPFQMPAD SwissProt Entrez-Gene
Orthologous residues
SMAD1 (human): S214‑p, SMAD1 (mouse): S214‑p, SMAD1 (rat): S214‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HaCaT (keratinocyte)
Cellular systems studied:  cell lines
Species studied:  human